While discipline is often praised in the fitness world, taking "healthy" routines to the extreme can trigger a chronic immune ...

Cambridge, USA-based clinical-stage biotechnology company Caldera Therapeutics, which is developing the first-in-class ...

CK0804, a novel Treg therapy, gains FDA orphan drug status for myelofibrosis, promising new hope for patients with limited treatment options. CK0804, an investigational allogeneic regulatory T cell ...

Please provide your email address to receive an email when new articles are posted on . The interleukin-5 inhibitor benralizumab yielded durable remission rates in EGPA. The drug showed no new safety ...

Current NCAA eligibility rules will remain in place for the rest of this academic year as well as the 2026-27 academic year. Kirby Lee / Imagn Images A possible change in college eligibility rules to ...

Introduction: Inflammatory mechanisms assume a pivotal role in bullous pemphigoid (BP). IL-31, IL-5, and the systemic immunoinflammatory index (SII) are emerging markers of inflammatory activity, but ...

Mepolizumab significantly reduced the annualized rate of moderate or severe exacerbations in COPD with an eosinophilic phenotype. Some 20% to 40% of COPD patients have elevated blood eosinophil counts ...

Extended treatment with benralizumab led to sustained remission, reduced glucocorticoid burden, eosinophil depletion, and low relapse rates among patients with eosinophilic granulomatosis with ...

Mepolizumab significantly reduced asthma exacerbations and oral corticosteroid use in patients with SEA, with or without CRSwNP, in a real-world setting. Improvements in lung function and asthma ...